A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of MEDiastinal lymphadenopathY (REMEDY) (REMEDY)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00932854 |
|
Recruitment Status
: Unknown
Verified October 2011 by Sam Janes, University College London Hospitals.
Recruitment status was: Active, not recruiting
First Posted
: July 3, 2009
Last Update Posted
: October 18, 2011
|
Sponsor:
University College London Hospitals
Information provided by (Responsible Party):
Sam Janes, University College London Hospitals
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Enlarged glands in the chest (mediastinal lymphadenopathy) is a common problem and may have a variety of different causes. In the past an operation (mediastinoscopy) was required to diagnose the glands. Endobronchial ultrasound (EBUS) is a new procedure that may be able to diagnose these glands without the need for mediastinoscopy. The REMEDY trial aims to examine whether EBUS can reduce the number of mediastinoscopies and healthcare costs in patients with enlarged glands in the chest.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Isolated Mediastinal Lymphadenopathy Sarcoidosis Tuberculosis Lung Cancer Lymphoma | Procedure: EBUS | Not Applicable |
Although the literature is replete with data on the utility of Endobronchial Ultrasound for lung cancer, there are very few data available on its role in the diagnosis of isolated mediastinal lymphadenopathy due to other causes such as sarcoid, tuberculosis or lymphoma. The REMEDY trial aims to evaluate the accuracy of EBUS in this setting and assess any reduction in the number of mediastinoscopies and healthcare costs.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 75 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of Isolated MEDiastinal lymphadenopathY (REMEDY) |
| Study Start Date : | July 2009 |
| Actual Primary Completion Date : | April 2011 |
| Estimated Study Completion Date : | October 2011 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Ultrasound
U.S. FDA Resources
| Arm | Intervention/treatment |
|---|---|
|
Experimental: EBUS
All patients in the trial will undergo EBUS for the diagnosis of isolated mediastinal lymphadenopathy. If this investigation is negative then the patient will be referred for mediastinoscopy.
|
Procedure: EBUS
Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
Other Names:
|
Primary Outcome Measures
:
- Number of mediastinoscopies prevented and healthcare costs [ Time Frame: At diagnosis ]
Secondary Outcome Measures
:
- Length of hospital stay [ Time Frame: At diagnosis ]
- Sensitivity and false negative rate of endobronchial ultrasound [ Time Frame: At study completion ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Consecutive patients with undiagnosed mediastinal lymphadenopathy (>1cm in short axis) on CT or PET-CT scan for whom pathological evaluation is clinically indicated.
Exclusion Criteria:
- Patients without informed consent, those with anterior mediastinal lesions or with contra-indications to EBUS or mediastinoscopy will be excluded.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00932854
Locations
| United Kingdom | |
| University College London Hospital | |
| London, United Kingdom, WC1E 5DB | |
Sponsors and Collaborators
University College London Hospitals
Investigators
| Principal Investigator: | Sam Janes, MD PhD | University College, London | |
| Study Director: | Neal Navani, MD | Univeristy College London |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Sam Janes, Reader in Respiratory Medicine, University College London Hospitals |
| ClinicalTrials.gov Identifier: | NCT00932854 History of Changes |
| Other Study ID Numbers: |
REMEDY 09/0090 |
| First Posted: | July 3, 2009 Key Record Dates |
| Last Update Posted: | October 18, 2011 |
| Last Verified: | October 2011 |
Keywords provided by Sam Janes, University College London Hospitals:
|
Mediastinal lymphadenopathy EBUS Bronchoscopy Sarcoidosis |
Additional relevant MeSH terms:
|
Tuberculosis Sarcoidosis Lymphadenopathy Mycobacterium Infections Actinomycetales Infections |
Gram-Positive Bacterial Infections Bacterial Infections Lymphoproliferative Disorders Lymphatic Diseases |